Patricia Font

List of Publications by Year
in descending order

39 papers	1,206 citations	567281 15 h-index	377865 34 g-index
44 all docs	44 docs citations	44 times ranked	1271 citing authors

#	Article	IF	Citations
1	Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia, 2012, 26, 1730-1741.	7.2	217
2	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550.	7.2	97
3	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusionâ€“Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Journal of Clinical Oncology, 2021, 39, 48-56.	1.6	80
4	Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia, 2021, 35, 2119-2124.	7.2	74
5	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma, 2013, 54, 472-475.	1.3	66
6	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 673-673.	1.4	66
7	Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Annals of Hematology, 2013, 92, 19-24.	1.8	65
8	Interobserver variance in myelodysplastic syndromes with less than 5Â% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2Â% blasts. Annals of Hematology, 2015, 94, 565-573.	1.8	62
9	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	3.5	36
10	Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?. Translational Research, 2008, 151, 240-245.	5.0	29
11	Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leukemia Research, 2006, 30, 957-963.	0.8	24
12	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. Cancers, 2019, 11, 1364.	3.7	23
13	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
14	Flow cytometric analysis of myelodysplasia: Preâ€analytical and technical issuesâ€”Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
15	Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).. Journal of Clinical Oncology, 2020, 38, 7506-7506.	1.6	15
16	Multicenter comparison of CD34+ myeloid cell count by flow cytometry in lowâ€risk myelodysplastic syndrome. Is it feasible?. Cytometry Part B - Clinical Cytometry, 2018, 94, 527-535.	1.5	9
17	Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood, 2018, 132, 463-463.	1.4	9
18	Expression of CD7 in myelodysplastic syndromes (MDS): Is this a truly prognostic factor?. Leukemia Research, 2008, 32, 185-186.	0.8	8

#	Article	IF	Citations
19	Azacitidine for the treatment of patients with acute myeloid leukemia with 20%â€“30% blasts and multilineage dysplasia. Advances in Therapy, 2011, 28, 1-9.	2.9	8
20	Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility. International Journal of Hematology, 2022, 115, 61-68.	1.6	8
21	A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).. Journal of Clinical Oncology, 2016, 34, 7060-7060.	1.6	7
22	Plasma endothelin-1 levels after stem cell transplantation. Bone Marrow Transplantation, 2000, 26, 1199-1204.	2.4	6
23	A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD. Blood, 2015, 126, 2896-2896.	1.4	6
24	Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 263-277.	1.9	5
25	Clinical utility of targeted nextâ€generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition. Molecular Oncology, 2021, 15, 2273-2284.	4.6	5
26	Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2020, 136, 17-17.	1.4	4
27	Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators. Blood, 2012, 120, 3593-3593.	1.4	3
28	On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 2021, 138, 2598-2598.	1.4	3
29	Myelodysplastic syndrome after breast cancer. The challenge of late complications in long-term survivors. Leukemia Research, 2016, 49, 88-89.	0.8	2
30	Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. Cancers, 2021, 13, 3001.	3.7	2
31	Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2019, 134, 4248-4248.	1.4	2
32	Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Â¿Is the Threshold of 20% Bone Marrow Blasts Reproducible?. Blood, 2021, 138, 2607-2607.	1.4	2
33	Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study. European Journal of Cancer Care, 2017, 26, e12426.	1.5	1
34	The Challenge Of Quantifying CD34+ Myeloid Cells In Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts. Reproducibility Among 6 Flow Cytometry Observers. Blood, 2013, 122, 2769-2769.	1.4	1
35	P041 Potential value of flow cytometry immunophenotyping in the diagnosis of hypoplastic MDS. Leukemia Research, 2009, 33, S82.	0.8	0
36	Multicenter Comparison of CD34+ Myeloid Cell Count by Flow Cytometry in Low-Risk Myelodysplastic Syndrome. Is It Feasible?. Leukemia Research, 2017, 55, S98-S99.	0.8	0

#	Article	IF	Citations
37	Inter-Observer Discordance With The Diagnosis Of Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts: Unilineage Vs Multilineage Dysplasia and Reproducibility Of The Threshold Of 2% Blasts. Blood, 2013, 122, 2768-2768.	1.4	0
38	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML) and Adverse Karyotype. Subanalisis from the Alma Study. Blood, 2014, 124, 945-945.	1.4	0
39	Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes. Blood, 2018, 132, 3085-3085.	1.4	0